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Background: Children with Down syndrome (DS) are at high risk of infectious toxicity when treated with acute
lymphoblastic leukemia chemotherapy protocols optimized in children without DS. Our objective was to determine
if children with DS and acute myeloid leukemia (AML) have a different risk of infection when treated with
chemotherapy protocols developed for children with DS compared to AML treatment protocols developed for
children without DS.
Methods: We conducted a retrospective, population-based cohort study that included DS children ≤ 18 years of
age with de novo, non-M3 AML diagnosed between January 1995 and December 2004, and treated at 15 Canadian
centers. Patients were monitored for infection from initiation of AML treatment until recovery from the last cycle of
chemotherapy, conditioning for hematopoietic stem cell transplantation, relapse, persistent disease or death
(whichever occurred first). Trained research associates abstracted all information from each site.
Results: There were 31 children with DS included; median age was 1.7 (range 0.1-11.1) years. Eleven were treated
according to a DS-specific protocol while 20 were treated with non-DS specific protocols. A total of 157 courses of
chemotherapy were delivered. Microbiologically documented sterile site infection occurred in 11.9% and 14.3% of
DS-specific and non-DS specific AML treatment courses respectively. Sepsis was rare and there were no infection-
related deaths. In multiple regression, treatment with a DS-specific protocol was independently associated with a
reduction in microbiologically documented sterile site infection (adjusted odds ratio (OR) 0.65, 95% confidence
interval (CI) 0.42-0.99; P = 0.044), and clinically documented infection (adjusted OR 0.36, 95% CI 0.14-0.91; P = 0.031)
but not bacteremia (adjusted OR 0.73, 95% CI 0.44-1.22; P = 0.231).
Conclusions: Our study suggests that children with DS do not experience excessive infectious toxicity during
treatment for AML compared to children without DS. Incorporation of DS-specific AML treatment protocols is
associated with a more favorable infection profile for children with DS-AML.
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Children with Down syndrome (DS) have an approxi-
mately 10-20 fold increased risk of developing leukemia
compared with non-DS children [1,2]. Consequently, chil-
dren with DS comprise approximately 3% of pediatric
acute lymphoblastic leukemia (ALL) [3] and up to 15% of
pediatric acute myeloid leukemia (AML) cases enrolled in
clinical trials [4]. Recent studies have provided new
insights into the unique epidemiology, pathogenesis and
treatment response of ALL and AML in children with DS
[2]. AML occurs at a younger age in children with DS [5],
is defined by somatic GATA1 mutations [6] and shows
increased sensitivity to chemotherapeutic agents such as
cytarabine and anthracyclines [7,8].
Excessive mortality of children with DS has been
observed during treatment for ALL. These deaths have
primarily been attributed to infection after chemotherapy-
induced myelosuppression during induction as well as
post-remission therapy [9-12]. These observations have
led to treatment modifications specifically for DS-ALL. In
contrast to the known risk of infection-related mortality
for children with DS undergoing ALL treatment, there is a
paucity of data defining the risk of infection among
children with DS undergoing AML therapy, either with
DS-specific or standard AML treatment protocols. The
objective of our study was to determine if children with
DS-AML have a lower risk of infection when treated with
DS-specific AML chemotherapy protocols compared to
standard AML treatment protocols developed for children
without DS.Methods
In this retrospective, population-based cohort study, we
included children with newly diagnosed AML who had a
diagnosis of DS and were treated at one of 15 Canadian
centers that care for children with cancer in each province
except for Saskatchewan. This manuscript is a follow-up
analysis of a larger study in which outcomes of all children
with newly diagnosed AML in Canada were analyzed [13].Study sample
We included children with DS (age ≤ 18 years) who
were diagnosed with AML between January 1, 1995 and
December 31, 2004. We excluded those with acute
promyelocytic leukemia, secondary AML and previous
diagnosis of immunodeficiency. We collected infor-
mation on infections from the start of AML treatment
until hematopoietic recovery from the last cycle of
chemotherapy, start of conditioning for hematopoietic
stem cell transplantation (HSCT), relapse, change in
protocol therapy due to refractory disease, or death
(whichever occurred first). Trained clinical research as-
sociates abstracted and coded the relevant information(see below). Intensive chemotherapy was defined as
treatment expected to result in profound neutropenia.
Outcome measures
We described the occurrence of microbiologically docu-
mented sterile site infection [14], bacteremia and clinically
documented infection during each course of chemother-
apy. Sterile site cultures with common contaminants such
as coagulase-negative Staphylococcus were only con-
sidered true infection if there were two or more positive
cultures within the same episode or if the infection was
associated with sepsis [15,16]. Sepsis was defined as
systemic inflammatory response syndrome in the presence
of suspected or proven infection and organ dysfunction
according to international consensus guidelines [17,18].
We classified clinically documented infections based upon
the Centers for Disease Control and Prevention (CDC)
definitions of nosocomial infections [19]. Bacteremia was
included as a sterile site microbiologically documented
infection such that any true bacteremia would be
counted in both outcomes, but would not be included
as a clinically documented infection unless associated
with a specific site of infection such as pneumonia or
cellulitis.
Potential predictors
We described demographic and course characteristics
according to whether the child was treated with a DS-
specific or a non-DS specific AML treatment protocol.
A DS-specific AML protocol was defined as a treatment
protocol used only for children with DS and not a treat-
ment protocol that included both children with and
without DS. In addition, the following variables were
evaluated to determine if they were potential confoun-
ders in the relationship between protocol type and infec-
tion outcomes: child age at diagnosis, diagnosis prior to
January 1, 2000, cumulative dose of cytarabine in grams/
m2, severe neutropenia defined as an absolute neutrophil
count (ANC) ≤ 500/uL at the start of the course, neutro-
penia >15 days (threshold chosen a priori), and number
of days during which systemic corticosteroids were
administered for any reason.
Statistics
In order to compare demographic features of patients
treated with DS and non-DS specific protocols, continuous
variables were compared using the Wilcoxon rank sum test
and categorical variables were compared using the Chi
square or Fisher’s exact test as appropriate. Course charac-
teristics were not statistically compared since courses were
not independent within an individual child. Factors associ-
ated with the occurrence of microbiologically documented
sterile site infection, bacteremia and clinically documented
infection were examined using a repeated measures logistic
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association was expressed as an odds ratio (OR) with 95%
confidence interval (CI). To determine if treatment with a
DS-specific protocol was independently associated with
infection outcomes, variables significant in univariate
analysis were added to the multiple regression model that
contained treatment protocol type. Spearman correlation
coefficients were evaluated to ensure lack of co-linearity
before addition to the model. All tests of significance
were two-sided, and statistical significance was defi-
ned as P <0.05. Statistical analysis was performed
using the SAS statistical program (SAS-PC, version 9.3;
SAS Institute Inc., Cary, NC).
Ethical approvals
This study was approved by the Research Ethics Board
at The Hospital for Sick Children and local Research
Ethics Boards of the 14 other participating sites
(McMaster University-Hamilton Health Sciences/Faculty
of Health Sciences Research Ethics Board, Montreal
Children’s Hospital Research Ethics Board, Children’s
Hospital of Eastern Ontario Research Ethics Board, Uni-
versity of Winnipeg Research Ethics Board, University of
British Columbia/Children’s and Women’s Health Centre
of British Columbia Research Ethics Board, Centre
Hospitalier Universitaire Sainte-Justine Research Ethics
Board, University of Calgary Conjoint Health Research
Ethics Board, IWK Research Ethics Board, Queen’s Uni-
versity-Health Sciences Research Ethics Board, UniversityTable 1 Characteristics of children with Down syndrome at di
DS-specific AML p
Child characteristics at diagnosis
Male (%) 9 (81.8)
Median age in years (IQR) 1.5 (0.8, 2.3)
Median WBC (×109/L)(IQR) 5.4 (3.1, 21.1)
Median ANC (×109/L)(IQR)a 1.1 (0.6, 2.6)
Median hemoglobin (g/L)(IQR) 82.0 (78.0, 107.0)
Median platelet count (×109/L )(IQR)b 33.5 (12.0, 57.0)
Cytogenetics (%)
Normal karyotype 2 (18.2)
t(8;21), inv16 or t(16;16) 0 (0.0)




Registered on a study (%) 2 (18.2)
Time on any chemotherapy (median days) (IQR) 199.0 (177.0, 260.0)
Time on intensive chemotherapy (median days) (IQR) 135.0 (120.0, 143.0)
Abbreviations: IQR interquartile range, WBC white blood cell, ANC absolute neutroph
aANC not available at diagnosis for two patients in the non-Down syndrome protoc
bPlatelet count not available at diagnosis for one patient in both groups.of Western Ontario Research Ethics Board for Health
Science Research Involving Human Subjects, Memorial
University Human Investigation Committee, Centre
Hospitalier Universitaire de Quebec Research Ethics
Board, University of Alberta Health Research Ethics
Board-Biomedical Panel, Centre Hospitalier Universitaire
de Sherbrooke Research Ethics Board). As this was a
retrospective review study the Research Ethics Board at
The Hospital for Sick Children and those at the 14 other
participating sites waived the need for written informed
consent.
Results
The primary AML study included 341 patients; 168
(49.3%) were male and the median age was 7.1 (inter-
quartile range 2 to 13.5) years [13]. Thirty-one children
with DS were included in the current analysis; the
median age was 1.7 (range 0.1 to 11.1) years. Eleven
were treated with DS-specific AML protocols while 20
were treated with non-DS specific AML protocols. The
DS-specific AML protocols were: Children’s Oncology
Group (COG) A2971 (n = 9) and the AMKL-DS low
dose cytarabine protocol (n = 2). The non-DS specific
protocols were: Pediatric Oncology Group (POG) 8821
(n = 1), CCG 213 (n = 2), CCG 2891 (n = 4), and POG
9421 (n = 13). Characteristics including age and time on
intensive chemotherapy were not significantly different
between those treated with DS-specific versus non-DS
specific AML protocols (Table 1).agnosis of acute myeloid leukemia (N = 31)
rotocol (N = 11) Non-DS specific AML protocol (N = 20) P value
11 (55.0) 0.241
2.2 (1.5, 2.9) 0.132
7.6 (4.8, 16.7) 0.397
1.6 (0.8, 4.1) 0.312
92.5 (59.0, 110.0) 0.870








168.5 (136.5, 225.0) 0.143
153.5 (129.0, 214.0) 0.094
il count, AML acute myeloid leukemia, DS Down syndrome.
ol group.
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apy observed for this analysis are shown in Table 2.
Microbiologically documented sterile site infection
occurred in 11.9% of DS-specific and 14.3% of non-DS
specific AML treatment courses. Sepsis was rare and
there were no infection-related deaths.
We then evaluated factors potentially associated with
the occurrence of microbiologically documented sterile
site infection, bacteremia and clinically documented
infection (Table 3). Treatment with a DS-specific AML
protocol was significantly associated with a reduction in
these infection outcomes. In multiple regression, treat-
ment with a DS-specific protocol was independently
associated with a reduction in microbiologically docu-
mented sterile site infection (adjusted OR 0.65, 95% CI
0.42 to 0.99; P = 0.044), and clinically documented infec-
tion (adjusted OR 0.36, 95% CI 0.14 to 0.91; P = 0.031) but
not bacteremia (adjusted OR 0.73, 95% CI 0.44 to 1.22;
P = 0.231).
The organisms underlying the infections observed
in children with DS treated with both DS-specific and
non-DS specific AML protocols are shown in Table 4.
Discussion
In this population-based study of children with DS
and AML, we found that microbiologically docu-
mented sterile site infection occurred in less than
15% of chemotherapy courses, whether children with
DS were treated with a DS-specific or standard AML
treatment protocol. Sepsis was rare and there were noTable 2 Course characteristics and infection outcomes accord
DS-
Course characteristics
Number with neutropenia (ANC <0.5 x109) at start of course (%) 5 (8
Median days with neutropenia (IQR) 11.0
Median days receiving steroids (IQR) 0.0 (
Supportive care
Co-trimoxazole prophylaxis (%) 41 (
Fluconazole prophylaxis (%) 28 (
Infection outcomesb
Microbiologically documented sterile site infection (%) 7 (1
Bacteremia (%) 6 (1
Sterile site Gram-positive bacteria (%) 5 (8
Sterile site Gram-negative bacteria (%) 2 (3
Sterile site fungus (%) 0 (0
Clinically documented infection (%) 7 (1
Sepsis (%) 1 (1
Infectious death (%) 0 (0
Abbreviations: ANC absolute neutrophil count, IQR interquartile range, AML acute m
aANC not available at start of 2 courses.
bInfection outcomes represent at least one event per course.infection-related deaths. We found that treatment
with a DS-specific AML protocol was associated with
fewer microbiologically documented sterile site infec-
tion and clinically documented infection in children
with DS-AML.
The relatively low risk of infection for children with
DS undergoing AML therapy is surprising. More than
60% of non-DS children with AML treated according to
the CCG 2961 protocol experienced an infection during
each course of chemotherapy [20]. Similarly, in a more
recent pediatric AML phase III trial, AAML0531, 30 to
60% of courses were complicated by sterile site infec-
tions [21]. While treatment with a DS-specific AML
protocol may partially explain the low rate of infection
in this cohort, it remains unclear why children with DS
treated with non-DS specific AML protocols also experi-
enced a low rate of infection. It is possible that clinicians
making decisions regarding treatment modifications or
enhanced supportive care for children with DS-AML were
influenced by the data about excess infection-related
complications in DS-ALL. Another factor to consider is
that neither CCG 2961 nor AAML0531 infection reports
had the ability to evaluate common contaminants and to
distinguish these from true bacteremia; this issue may
have artificially increased the infection rates on those
studies.
Highly aggressive chemotherapy protocols for AML
were associated with excessive mortality in children with
DS [5]. In contrast, standard and reduced intensity AML
protocols have resulted in superior survival amonging to acute myeloid leukemia protocol type (N = 157)
specific AML protocol (N = 59) Non-DS AML protocol (N = 98)
.4) 12 (12.5)a
(3.0, 21.0) 16.0 (7.0, 25.0)











yeloid leukemia, DS Down syndrome.





Odds ratio (CI) P value Odds ratio (CI) P value Odds ratio (CI) P value
Down syndrome-specific treatment protocol 0.42 (0.28, 0.64) <0.0001 0.48 (0.29, 0.78) 0.003 0.25 (0.10, 0.60) 0.002
Age in years 1.01 (0.99, 1.03) 0.349 1.01 (0.98, 1.03) 0.577 1.01 (0.99, 1.03) 0.261
Diagnosed prior to January 1, 2000 0.79 (0.60, 1.03) 0.080 0.75 (0.56, 1.00) 0.052 0.95 (0.75, 1.22) 0.703
Cumulative dose of cytarabine (g/m2) 1.03 (1.02, 1.05) 0.0001 1.03 (1.01, 1.05) 0.001 0.99 (0.97, 1.01) 0.184
Neutropenia (ANC <0.5 ×109) at start of course 1.01 (0.72, 1.43) 0.936 0.82 (0.56, 1.22) 0.336 1.88 (1.38, 2.56) <0.0001
Greater than 15 days with neutropenia 2.50 (1.89, 3.32) <0.0001 2.45 (1.83, 3.36) <0.0001 2.81 (2.16, 3.66) <0.0001
Days receiving steroids 1.08 (1.06, 1.11) <0.0001 1.07 (1.05, 1.10) <0.0001 1.07 (1.05, 1.09) <0.0001
Abbreviations: ANC absolute neutrophil count, CI confidence interval.
Table 4 Microbiologically documented infection observed
during acute myeloid leukemia therapy in children with
Down syndrome
DS-specific AML
protocol (N = 12)
Non-DS specific AML









Enterococcus faecalis 0 2
Othera 0 1
Gram negative
Escherichia coli 1 3
Klebsiella pneumoniae 0 1
Enterobacter cloacae 0 2
Othersb 1 2
Fungus*
Candida species 0 2
Virus*
Herpes simplex virus 1 1
Respiratory syncytial virus 1 3
Torovirus 1 4
Othersc 1 5
Clostridium difficile* 1 5
Abbreviations: AML acute myeloid leukemia, DS Down syndrome.
*For bacterial infections other than C. difficile, only sterile site positive cultures
are shown. For fungi, viruses and C. difficile, both sterile and non-sterile site
positive cultures are shown.
aOther: beta-hemolytic Streptococcus (n = 1).
bOthers: Citrobacter freundii (n = 1) for Down syndrome protocol group;
Enterobacter species (n = 1) and Haemophilus influenza (n = 1) for non-Down
syndrome protocol group.
cOther: parvovirus (n = 1) for Down syndrome protocol group; parainfluenza
(n = 3) and rotavirus (n = 2) for non-Down syndrome protocol group.
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AML [22,23], supporting the development of DS-specific
AML treatment protocols. The reason why DS-specific
AML protocols are associated with fewer infections may
be related to the reduced intensity of therapy associated
with these protocols. It has been shown that higher
cumulative cytarabine dose is associated with higher risk
of infection [24,25]. However, infection risk did not
correlate with cumulative cytarabine dose in the report
by the Japanese Children’s Cancer and Leukemia Study
Group (JCCLSG) AML 9805 in which highest infection-
related death (12.5%) among children with DS-AML
occurred after a cumulative cytarabine dose of 12.6 g/m2
[26]. In contrast, treatment-related mortality was 5% in
BFM98 for children with DS-AML after a cumulative
cytarabine dose of 29 g/m2 and 5% in NOPHO AML93
with a cumulative cytarabine dose of 48.6 g/m2 [27,28].
Interestingly, the cumulative dose of cytarabine and
anthracycline between DS-specific and non-DS specific
AML protocols used in our cohort is overall comparable
with the exception of the AMKL-DS low-dose cytarabine
regimen and POG 8821 (see Additional file 1). The in-
corporation of additional chemotherapy agents such as
etoposide and dexamethasone and intensive-timing
chemotherapy delivery in non-DS specific AML proto-
cols may perhaps account for this difference in infec-
tious toxicities.
Different cooperative groups are considering further
reduction of treatment intensity for children with DS-
AML in view of toxicity concerns and the unique en-
hanced sensitivity of DS-AML cells to cytarabine
[7,8,29]. However, in light of the low infectious morbid-
ity and mortality in our study, further treatment inten-
sity reduction might not provide additional safety
advantages but may compromise event-free survival
rates in children with DS-AML. Subsequent trials for
DS-AML will need to carefully consider whether further
reduction in treatment intensity is warranted and in
contrast, may elect to further enhance supportive care in
order to further reduce toxic events.
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this was a population-based study which allowed us to
capture all patients with DS-AML treated as opposed to
only those treated at a single institution or registered on
clinical trials. Therefore, we believe that the present
study provides an accurate estimate of the incidence of
different infection outcomes within this population. The
rigor in identifying infections using a common group of
well-trained personnel represents another strength of
this study. In addition, each outcome measure was
examined at a course level and not a patient level; this
approach allowed us to evaluate factors that are expec-
ted to change between courses. However, interpretation
and generalization of our results require some caution
due to the retrospective nature and the small sample size
of our study. More specifically, the small number of
children included in our study limits the precision of
estimates although there is no reason to suspect selec-
tion bias may have occurred given the population-based
retrospective nature of the study.Conclusion
In conclusion, our study suggests that children with DS-
AML do not experience excessive infectious toxicity dur-
ing treatment for AML compared to the general pediatric
population without DS. In children with DS, treatment
protocols specifically developed for DS-AML were associ-
ated with a more favorable profile of infectious toxicity
compared to standard AML treatment protocols, support-
ing the development of specific treatment approaches for
this distinct form of pediatric AML.Additional file
Additional file 1: Comparison of DS-specific and non-DS specific
AML chemotherapy regimens.Abbreviations
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